Ryutaro Nakashima

发表

Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.

S. Kume, Koji Matsumoto, M. Inoue, 2014, European journal of pharmacology.

Neural cells play an inhibitory role in pancreatic differentiation of pluripotent stem cells

K. Kume, S. Kume, Ryutaro Nakashima, 2015, Genes to cells : devoted to molecular & cellular mechanisms.

Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.

M. Yachi, J. Ohsumi, K. Araki, 2009, Journal of pharmacological sciences.

Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.

S. Ito, Koji Matsumoto, Masakazu Hirouchi, 2015, ACS medicinal chemistry letters.

Intracellular calcium release channels: an update

A. Marks, G. Santulli, Qi Yuan, 2017, The Journal of physiology.

Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.

T. Fujiwara, A. Okuno, Jun Tanaka, 2009, European journal of pharmacology.

Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.

Koji Matsumoto, N. Watanabe, M. Inoue, 2014, Bioorganic & medicinal chemistry letters.

Title of the report : Intracellular calcium release channels : an update

A. Marks, G. Santulli, Qi Yuan, 2017 .

Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.

T. Fujiwara, A. Okuno, Jun Tanaka, 2009, European journal of pharmacology.

Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.

Koji Matsumoto, Masakazu Hirouchi, N. Watanabe, 2015, Bioorganic & medicinal chemistry.